Roche
NICE signs-off Roche’s Gazyvaro for leukaemia
June 2, 2015Sales and Marketing Allergan, Bayer, CLL, Carole Longson, Eylea, Gazyvaro, NICE, Ozurdex, Roche, diabetic macular edema, leukaemia
NICE has given positive final guidance backing the use of Roche’s Gazyvaro for people with chronic lymphocytic leukaemia (CLL). Earlier …
Amgen hires head of Europe from Roche
June 2, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Corinne Le Goff, Roche
Corinne Le Goff is joining Amgen to be its senior vice president and head of the European region for the …
Roche lung cancer treatments perform
May 14, 2015Sales and Marketing MPDL3280A, Roche, alectinib, immunotherapy
Roche has revealed promising trial data from two lung cancer treatments with one improving survival and the other shrinking tumours. …
Pharma reveals its ASCO presentation data
May 12, 2015Research and Development, Sales and Marketing ASCO, AZ, AbbVie, Roche, chicago, data
AstraZeneca, Genentech and AbbVie have all revealed which cancer drugs they will show data for at The American Society of …
Boardroom shuffles at GSK and Roche
May 8, 2015Medical Communications, Sales and Marketing GSK, Novartis, Roche, ViiV, changes, leadership
GlaxoSmithKline and Roche have announced the latest changes to its leadership teams as the companies regroup for the year ahead. …
AstraZeneca partners with PatientsLikeMe
April 14, 2015Sales and Marketing AstraZeneca, Lupus, PatientsLikeMe, Roche, diabetes, oncology, respiratory disease
AstraZeneca has signed a five-year agreement with PatientsLikeMe to give the pharma firm access to the latter’s global network of …
EU nod for Roche cancer drug and chemotherapy
April 8, 2015Sales and Marketing Cancer, Roche, avastin, bevacizumab, cervical, chemotherapy, wet AMD
The European Commission has approved Roche’s Avastin in combination with standard chemotherapy for women with advanced cervical cancer. Avastin (bevacizumab) …
Roche subsidiary Genentech expands in manufacturing
March 31, 2015Manufacturing and Production, Sales and Marketing Genentech, Roche, hillsboro, manufacturing, oregon
Californian drugmaker Genentech is planning a $125 million expansion at its Hillsboro manufacturing centre in Oregon. The Roche subsidiary plant …
Big pharma teams with government on genomic research
March 27, 2015Research and Development, Sales and Marketing AbbVie, Alexion Pharmaceuticals, AstraZeneca, Biogen, Cameron, Dimension Therapeutics, GSK, Genomic, Genomics england, Helomics, Roche, Takeda, UCB, UK, genomes
Ten firms will partner up with Genomics England to develop new diagnostics and treatments for people with rare diseases and …
Breast cancer treatment market booming
March 19, 2015Research and Development, Sales and Marketing Frost, Herceptin, Kadcyla, Roche, breast cancer, oncology, targeted, tykerb
The increased use of combined targeted therapies for breast cancer is set to lift the market and improve progression-free disease …
Boehringer eyes Ofev success in IPF and beyond
March 16, 2015Sales and Marketing Boehringer, Esbriet, Roche, ingelheim, inpulsis, ipd, ofev
Experts say the launch of Boehringer Ingelheim’s new treatment for idiopathic pulmonary fibrosis (IPF) offers stiff competition to Roche’s Esbriet …
NICE approves Roche’s Gazyvaro and Novartis’ Xolair
March 11, 2015Research and Development, Sales and Marketing Gazyvaro, NICE, Novartis, Roche, Xolair, obinutuzumab, omalizumab
NICE today gave the green light to three new biological drugs, after recommending Roche’s Gazyvaro, GSK’s Arzerra and Novartis’ Xolair …
Doctors appeal to prescribe Avastin off-label
February 25, 2015Sales and Marketing Lucentis, NHS, NICE, Novartis, Roche, bevacizumab, wet AMD
NHS Clinical Commissioners have called for the removal of barriers preventing CCGs from prescribing Roche’s Avastin to treat wet age-related …
Merck puts HIV drug in shared patent pool
February 24, 2015Research and Development, Sales and Marketing AbbVie, Gilead, HIV, Merck, Raltegravir, Roche, isentress
Merck is teaming up with the Medicines Patent Pool (MPP) to license its paediatric HIV treatment in developing countries. The …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
